vs
Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and Hippo Holdings Inc. (HIPO). Click either name above to swap in a different company.
Hippo Holdings Inc. is the larger business by last-quarter revenue ($120.4M vs $85.1M, roughly 1.4× 4D Molecular Therapeutics, Inc.). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs 5.0%, a 17.8% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 18.2%). 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $9.1M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 18.9%).
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
Hippo Valley Estate is a sugar estate found near the town of Chiredzi in Chiredzi District of southeastern Zimbabwe, on the Runde River near the border with Mozambique.
FDMT vs HIPO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $85.1M | $120.4M |
| Net Profit | $19.4M | $6.0M |
| Gross Margin | — | — |
| Operating Margin | 17.3% | 5.6% |
| Net Margin | 22.8% | 5.0% |
| Revenue YoY | 8508900.0% | 18.2% |
| Net Profit YoY | 139.1% | -86.4% |
| EPS (diluted) | $0.43 | $0.31 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $85.1M | $120.4M | ||
| Q3 25 | $90.0K | $120.6M | ||
| Q2 25 | $15.0K | $117.3M | ||
| Q1 25 | $14.0K | $110.3M | ||
| Q4 24 | $1.0K | $101.9M | ||
| Q3 24 | $3.0K | $95.5M | ||
| Q2 24 | $5.0K | $89.6M | ||
| Q1 24 | $28.0K | $85.1M |
| Q4 25 | $19.4M | $6.0M | ||
| Q3 25 | $-56.9M | $98.1M | ||
| Q2 25 | $-54.7M | $1.3M | ||
| Q1 25 | $-48.0M | $-47.7M | ||
| Q4 24 | — | $44.2M | ||
| Q3 24 | $-43.8M | $-8.5M | ||
| Q2 24 | $-35.0M | $-40.5M | ||
| Q1 24 | $-32.4M | $-35.7M |
| Q4 25 | 17.3% | 5.6% | ||
| Q3 25 | -67983.3% | 81.3% | ||
| Q2 25 | -396373.3% | 3.4% | ||
| Q1 25 | -383007.1% | -41.3% | ||
| Q4 24 | — | 46.3% | ||
| Q3 24 | -1704400.0% | -5.4% | ||
| Q2 24 | -849120.0% | -40.7% | ||
| Q1 24 | -136200.0% | -38.7% |
| Q4 25 | 22.8% | 5.0% | ||
| Q3 25 | -63195.6% | 81.3% | ||
| Q2 25 | -364386.7% | 1.1% | ||
| Q1 25 | -342657.1% | -43.2% | ||
| Q4 24 | — | 43.4% | ||
| Q3 24 | -1461433.3% | -8.9% | ||
| Q2 24 | -699060.0% | -45.2% | ||
| Q1 24 | -115717.9% | -42.0% |
| Q4 25 | $0.43 | $0.31 | ||
| Q3 25 | $-1.01 | $3.77 | ||
| Q2 25 | $-0.98 | $0.05 | ||
| Q1 25 | $-0.86 | $-1.91 | ||
| Q4 24 | — | $1.81 | ||
| Q3 24 | $-0.79 | $-0.34 | ||
| Q2 24 | $-0.63 | $-1.64 | ||
| Q1 24 | $-0.66 | $-1.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $402.7M | $218.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $505.7M | $436.1M |
| Total Assets | $566.7M | $1.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $402.7M | $218.3M | ||
| Q3 25 | $305.1M | $247.7M | ||
| Q2 25 | $293.2M | $198.9M | ||
| Q1 25 | $321.4M | $140.9M | ||
| Q4 24 | $424.9M | $197.6M | ||
| Q3 24 | $501.9M | $191.2M | ||
| Q2 24 | $541.9M | $175.9M | ||
| Q1 24 | $525.9M | $223.4M |
| Q4 25 | $505.7M | $436.1M | ||
| Q3 25 | $369.0M | $421.5M | ||
| Q2 25 | $420.9M | $332.5M | ||
| Q1 25 | $469.7M | $322.8M | ||
| Q4 24 | $510.6M | $362.1M | ||
| Q3 24 | $552.9M | $326.4M | ||
| Q2 24 | $588.3M | $322.6M | ||
| Q1 24 | $600.6M | $351.2M |
| Q4 25 | $566.7M | $1.9B | ||
| Q3 25 | $424.0M | $1.9B | ||
| Q2 25 | $473.6M | $1.7B | ||
| Q1 25 | $515.7M | $1.5B | ||
| Q4 24 | $560.4M | $1.5B | ||
| Q3 24 | $604.0M | $1.5B | ||
| Q2 24 | $620.1M | $1.5B | ||
| Q1 24 | $629.9M | $1.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.6M | $9.2M |
| Free Cash FlowOCF − Capex | $28.5M | $9.1M |
| FCF MarginFCF / Revenue | 33.5% | 7.6% |
| Capex IntensityCapex / Revenue | 0.1% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.47× | 1.53× |
| TTM Free Cash FlowTrailing 4 quarters | $-109.9M | $14.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.6M | $9.2M | ||
| Q3 25 | $-46.5M | $16.9M | ||
| Q2 25 | $-43.4M | $24.7M | ||
| Q1 25 | $-47.8M | $-35.6M | ||
| Q4 24 | $-134.6M | $47.5M | ||
| Q3 24 | $-29.4M | $46.8M | ||
| Q2 24 | $-30.2M | $-10.6M | ||
| Q1 24 | $-29.1M | $17.7M |
| Q4 25 | $28.5M | $9.1M | ||
| Q3 25 | $-46.6M | $16.8M | ||
| Q2 25 | $-43.4M | $24.6M | ||
| Q1 25 | $-48.4M | $-35.7M | ||
| Q4 24 | $-138.4M | $47.2M | ||
| Q3 24 | $-31.2M | — | ||
| Q2 24 | $-30.6M | $-10.7M | ||
| Q1 24 | $-29.8M | $17.6M |
| Q4 25 | 33.5% | 7.6% | ||
| Q3 25 | -51765.6% | 13.9% | ||
| Q2 25 | -289620.0% | 21.0% | ||
| Q1 25 | -345635.7% | -32.4% | ||
| Q4 24 | -13837100.0% | 46.3% | ||
| Q3 24 | -1038966.7% | — | ||
| Q2 24 | -611840.0% | -11.9% | ||
| Q1 24 | -106421.4% | 20.7% |
| Q4 25 | 0.1% | 0.1% | ||
| Q3 25 | 101.1% | 0.1% | ||
| Q2 25 | 440.0% | 0.1% | ||
| Q1 25 | 4507.1% | 0.1% | ||
| Q4 24 | 378600.0% | 0.3% | ||
| Q3 24 | 59266.7% | 0.0% | ||
| Q2 24 | 6980.0% | 0.1% | ||
| Q1 24 | 2535.7% | 0.1% |
| Q4 25 | 1.47× | 1.53× | ||
| Q3 25 | — | 0.17× | ||
| Q2 25 | — | 19.00× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
